Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Antonella Tramutola, Andrea Arena, Chiara Cini, D. Allan Butterfield & Eugenio Barone. (2017) Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology. Expert Review of Neurotherapeutics 17:1, pages 59-75.
Read now
Read now
Jens Juul Holst, Remy Burcelin & Esther Nathanson. (2011) Neuroprotective properties of GLP-1: theoretical and practical applications. Current Medical Research and Opinion 27:3, pages 547-558.
Read now
Read now
Mahamood Edavalath & Jeffrey W Stephens. (2010) Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. Patient Preference and Adherence 4, pages 61-68.
Read now
Read now
Joshua J Neumiller, Travis E Sonnett, Lindy D Wood, Stephen M Setter & R Keith Campbell. (2010) Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 3, pages 215-226.
Read now
Read now
Estela Wajcberg & Amatur Amarah. (2010) Liraglutide in the management of type 2 diabetes. Drug Design, Development and Therapy 4, pages 279-290.
Read now
Read now
Articles from other publishers (16)
Raziyeh Salami, Marziyeh Salami, Alireza Mafi, Mohammad-Hossein Aarabi, Omid Vakili & Zatollah Asemi. (2023) Possible Mechanisms and Molecular Signaling of Incretins against the
Development of Type 2 Diabetes Mellitus. Current Molecular Pharmacology 16:4, pages 448-464.
Crossref
Crossref
Joseph Bailey, Maha Coucha, Deanna R. Bolduc, Faith N. Burnett, Amy C. Barrett, Mark Ghaly & Mohammed Abdelsaid. (2022) GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes. Diabetologia 65:9, pages 1541-1554.
Crossref
Crossref
Xuesong Zhang, Sisi Liu, Yukun Li, Yan Wang, Meimei Tian & Guoqiang Liu. (2016) Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study. PLOS ONE 11:6, pages e0156393.
Crossref
Crossref
Erin St. Onge, Shannon A. Miller & Carol Motycka. (2016) Liraglutide (Saxenda<sup>®</sup>) as a Treatment for Obesity. Food and Nutrition Sciences 07:04, pages 227-235.
Crossref
Crossref
Onno N Groeneveld, L Jaap Kappelle & Geert Jan Biessels. (2015) Potentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus. Journal of Diabetes Investigation 7:1, pages 5-16.
Crossref
Crossref
Abir Nachar, Diane Vallerand, Lina Musallam, Louis Lavoie, Alaa Badawi, John Arnason & Pierre S. Haddad. (2013) The Action of Antidiabetic Plants of the Canadian James Bay Cree Traditional Pharmacopeia on Key Enzymes of Hepatic Glucose Homeostasis. Evidence-Based Complementary and Alternative Medicine 2013, pages 1-9.
Crossref
Crossref
Maneesh V UdiawarStephen C Bain. (2017) Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult patients. Clinical Medicine Insights: Therapeutics 4, pages CMT.S7283.
Crossref
Crossref
Evan M. Sisson. (2012) Liraglutide: Clinical Pharmacology and Considerations for Therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31:9, pages 896-911.
Crossref
Crossref
Jeffrey W Stephens. (2010) The incretin system in the management of type 2 diabetes mellitus. Clinical Medicine 10:5, pages 491-495.
Crossref
Crossref
Wei Meng, Robert P. Brigance, Hannguang J. Chao, Aberra Fura, Thomas Harrity, Jovita Marcinkeviciene, Stephen P. O’Connor, James K. Tamura, Dianlin Xie, Yaqun Zhang, Herbert E. Klei, Kevin Kish, Carolyn A. Weigelt, Huji Turdi, Aiying Wang, Robert Zahler, Mark S. Kirby & Lawrence G. Hamann. (2010)
Discovery of 6-(Aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-
a
]pyrimidine-2-carboxamides as Potent, Selective Dipeptidyl Peptidase-4 (DPP4) Inhibitors
. Journal of Medicinal Chemistry 53:15, pages 5620-5628.
Crossref
Crossref
Giovanni AnfossiIsabella RussoKatia BonomoMariella Trovati. (2010) The Old and the New in the Treatment of Type 2 Diabetes: Focus on the Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Metformin. Clinical Medicine Insights: Therapeutics 2, pages CMT.S3420.
Crossref
Crossref
Samuel Grossman. (2012) Differentiating Incretin Therapies Based on Structure Activity, and Metabolism: Focus on Liraglutide. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29:12P2.
Crossref
Crossref
Joshua J Neumiller & R Keith Campbell. (2009) Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus. Annals of Pharmacotherapy 43:9, pages 1433-1444.
Crossref
Crossref
R. Keith Campbell & John R. White. (2008) More Choces Than Ever Before. The Diabetes Educator 34:3, pages 518-534.
Crossref
Crossref
John R. WhiteJr.Jr.. (2008) Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical Use. Clinical Diabetes 26:2, pages 53-57.
Crossref
Crossref
Natalie Diane Riediger, Shahin Shooshtari & Mohammed Hassan Moghadasian. (2007) The Influence of Sociodemographic Factors on Patterns of Fruit and Vegetable Consumption in Canadian Adolescents. Journal of the American Dietetic Association 107:9, pages 1511-1518.
Crossref
Crossref